替米沙坦聯(lián)合舒洛地特治療糖尿病腎�、笃谂R床觀察

　　[摘要]目的 探究替米沙坦聯(lián)合舒洛地特治療糖尿病腎病的臨床效果。方法 選取2015年3月～2017年3月我院收治的64例糖尿病腎�、笃诨颊咦鳛檠芯繉ο螅�采用隨機(jī)數(shù)字表法將其分為對照組和研究組，每組各32例。兩組患者均接受常規(guī)治療，對照組患者在常規(guī)治療的基礎(chǔ)上加服替米沙坦，研究組患者在常規(guī)治療的基礎(chǔ)上聯(lián)用替米沙坦和舒洛地特，兩組患者均治療8周。比較兩組患者的治療總有效率以及治療前和治療8周時的血清肌酐（Scr）、尿素氮（BUN）、尿蛋白排泄率（UAER）、超敏C-反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）含量。結(jié)果 研究組患者的治療總有效率（93.75%）高于對照組（68.75%），差異有統(tǒng)計學(xué)意義（P<0.05）。治療前，兩組患者的Scr、BUN、UAER比較，差異無統(tǒng)計學(xué)意義（P>0.05）。治療后，兩組患者的UAER明顯低于治療前，研究組患者的UAER明顯低于對照組，差異均有統(tǒng)計學(xué)意義（P<0.05）。治療前，兩組患者的hs-CRP、TNF-α含量比較，差異無統(tǒng)計學(xué)意義（P>0.05）。治療后，兩組患者的hs-CRP、TNF-α含量均明顯低于治療前，研究組患者的hs-CRP、TNF-α含量均明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 替米沙坦聯(lián)合舒洛地特治療糖尿病腎病臨床效果顯著，明顯優(yōu)于單用替米沙坦，建議臨床上推廣應(yīng)用。
　　[關(guān)鍵詞]替米沙坦；舒洛地特；糖尿病腎�。慌R床觀察
　　[中圖分類號] R654.2 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1674-4721（2018）2（b）-0126-03
　　Clinical observation of Telmisartan combined with Sulodexide for diabetic kidney disease at stage Ⅲ
　　FANG Hai-ming
　　Department of Nephrology，Kangmei Hospital in Puning City，Guangdong Province，Puning 515300，China
　　[Abstract]Objective To investigate the clinical efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic nephropathy.Methods 64 patients with diabetic kidney disease at stage Ⅲ treated in our hospital from March 2015 to March 2017 were selected as subjects of this study.They were divided into control group and study group with random number table method，32 cases in each group.Two groups of patients were treated with conventional therapy，the patients of control group were given Telmisartan on the addition of conventional treatment，the patients of study group were given Telmisartan and Sulodexide on the basis of conventional treatment，all patients were treated for 8 weeks.The total effective rate of treatment，the serum creatinine （Scr），urea nitrogen （BUN），microprojection rate （UAER），high sensitivity C-reactive protein （hs-CRP） and tumor necrosis factor-α （TNF-α） before and after 8 weeks of treatmen were comapred between two groups.Results The total effective rate in the study group （93.75%） was higher than that in the control group （68.75%），and the difference was statistically significant （P<0.05）.There was no significant difference in the Scr，BUN and UAER between the two groups before treatment （P>0.05）.After treatment，the UAER in both groups were lower than before treament，the UAER in the study group was significantly lower than that in the control group，and the difference was statistically significant （P<0.05）.Before treatment，there was no statistically significant difference in hs-CRP and TNF-α in the two groups （P>0.05）.After treatment，the levels of hs-CRP and TNF-α in both groups were significantly lower than before treatment，and the levels of hs-CRP and TNF-α in the study group were significantly lower than those in the control group，and the differences were statistically significant （P<0.05）.Conclusion The efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic kidney disease is significantly better than that of telmisartan alone，and it is recommended to be widely used clinically.

相關(guān)熱詞搜索：觀察 治療 聯(lián)合 期臨床 糖尿病腎病